Key Highlights
- Serum Institute of India (SII) has inked a landmark pact with Gates Medical Research Institute (Gates MRI) to mass‑produce the M72/AS01E tuberculosis vaccine.
- Once Phase‑III trials confirm efficacy, the deal envisages production for high‑burden nations, targeting cost‑effectiveness and wide accessibility.
- The collaboration reaffirms India’s stature as a premier vaccine manufacturing powerhouse amid the global TB eradication effort.
Detailed Insights
M72/AS01E is the most advanced candidate developed by GlaxoSmithKline and licensed to Gates MRI for large‑scale production. The agreement stipulates that SII will manufacture the vaccine once Phase‑III clinical trials prove its safety and efficacy. The vaccine, aimed at adults and adolescents, will complement the BCG vaccine, which primarily protects infants. By bringing the production under domestic control, India will be able to reduce costs and deliver doses to high‑prevalence countries promptly.
This partnership not only augments SII’s existing portfolio—powders for polio, measles, COVID‑19, and others—but also strengthens its role in global health security. It aligns with other SII collaborations on Ebola, dengue, and more, highlighting the institute’s expanding footprint in infectious disease research.
Key Concepts
- M72/AS01E vaccine – a recombinant subunit vaccine targeting pulmonary tuberculosis in adults and adolescents.
- Tuberculosis (TB) – a contagious bacterial infection primarily affecting the lungs.
- Phase III Clinical Trial – the definitive study that evaluates a vaccine’s efficacy and safety in a large population.
- BCG vaccine – the traditional vaccine for TB, mainly effective in infants and young children.
- Vaccine Manufacturing Capacity – the ability to produce vaccines at scale to meet global demand.